Bioanalytical measurement systems supplier Molecular Devices has partnered with Roche to develop Custom Ruthenium Nano-TRF Detection Platform.

Under the partnership, the custom technologies unit of Molecular Devices and the Discovery Technologies team at the Roche Innovation Center Basel of Pharma Research and Early Development (pRED) will develop a high-throughput detection system for drug discovery screens.

It will employ Roche’s Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF) assays.

The pRED screening teams in Basel and Shanghai are currently deploying the custom-developed Nano-TRF cartridge in their existing Molecular Devices SpectraMax Paradigm multimode microplate readers.

The teams will receive on-demand delivery of new cartridges and worldwide technical support.

Molecular Devices Global Services & Custom Solutions vice-president Shawn Laymon said: "We make the instruments that only existed as ideal specs in a team meeting or a protocol draft.

"We look forward to a continued relationship with Roche and to building new relationships with customers looking for a partner to help them create custom detection and analysis systems that meet their specific workflow needs."

Nano-TRF is a Ruthenium-based time-resolved assay utilized in high-throughput screening for drug discovery.

Molecular Devices’ SpectraMax Paradigm Multi-Mode Detection Platform features a cartridge-based system that expands the plate reader capability beyond traditional assays.

It will include applications like western blotting and imaging cytometry.